|
|
Post by brentie on Apr 6, 2016 9:52:59 GMT -5
|
|
|
|
Post by LosingMyBullishness on Apr 6, 2016 9:57:52 GMT -5
great find, brentie. Good article.
|
|
|
|
Post by mnholdem on Apr 6, 2016 11:23:00 GMT -5
Excerpts:
“We think we know what went wrong in Sanofi's hands, and we think we can fix that,” said Matthew Pfeffer, MannKind's CEO.
In recent months MannKind hired Michael Castagna, a former VP and global commercial lead at Amgen, as chief commercial officer, tasking him with building a sales force targeting primary care physicians. It is in the midst of finalizing a contract with a new advertising agency. The company also changed its strategy, identifying new patient populations to target, evaluating new pricing tactics, and reopening discussions with payers.
The “Surprise, it's Insulin!” campaign, which was developed by Havas Health, primarily targeted patients in the early stages of a diagnosis with type 2 diabetes.
Still, Pfeffer viewed Sanofi's strategy as flawed and said it failed to include potential patient populations. “They ignored segments, like type 1,” he said. “We think that was a mistake.”
---
It appears, now that the License & Collaboration Agreement is terminated, CEO Pfeffer can be a lot more vocal about Sanofi's mishandling of Afrezza
|
|
|
|
Post by lakon on Apr 6, 2016 12:08:44 GMT -5
FTA: “We're not going to hand over the product to another pharma company,” Pfeffer said. Lesson learned. Why does this remind me of the story about how Mr. Mann (RIP) got in the cochlear implant business? I think another meaning of FTA applies.  I'm bullish, not pumping. As our "friend" J. Cramer would say, "BUY BUY BUY." (Really, he's not pumping either? Right? Right.) |
|
|
|
Post by mnholdem on Apr 6, 2016 12:59:07 GMT -5
Just prior to the excerpt, the article states:
MannKind is scheduled to report its first-quarter earnings in May and is expected to present four abstracts at the upcoming American Diabetes Association scientific meeting in June. It plans to use those events as platforms to explain and promote its new plans to market the insulin, Pfeffer said. Once its own marketing strategy is established, MannKind may consider partnering with another organization.
“We're not going to hand over the product to another pharma company,” Pfeffer said.
So Matt appears to be providing a timeline which is in line with the Sanofi transition. Yesterday's PR stated that Sanofi would continue distribution of Afrezza until MannKind takes over in the 3rd Quarter, which begins July 1, a few weeks after "those events" (the 1Q16 earnings call and the June 2016-ADA Scientific Meetings) mentioned in the excerpt above.
---
Once again, shareholders must wait another few months. 
However, unlike the past, this does not mean that we'll get the silent treatment that has so often been the case in the past. Yesterday's PR appears to reiterate CEO Pfeffer's pledge to be more transparent, when it states, "In the coming weeks, we will roll out more information about our commercial team for Afrezza, the resources that we are designing for patients and physicians, and our plans for the future."
|
|
|
|
Post by sportsrancho on Apr 6, 2016 14:00:12 GMT -5
If we make it through July we'll be fine:-)
Time lines do add up mnholdem. I'm convinced there will be a flurry of activity!
|
|
|
|
Post by bradleysbest on Apr 6, 2016 14:31:01 GMT -5
Need Matt to stop doing the Ali rope-a-dope & throw some damn haymakers! Can't wait....
|
|
|
|
Post by mnkdorbust on Apr 6, 2016 14:32:19 GMT -5
Definitely awaiting the Flurry of activity! It has to be better than the embarrassment of riches  |
|
|
|
Post by sportsrancho on Apr 6, 2016 14:36:56 GMT -5
It better be epic! :-))
|
|
|
|
Post by lakon on Apr 6, 2016 14:48:22 GMT -5
I hope Matt has a sense of humor or we could be getting the silent treatment again.  |
|
|
|
Post by sportsrancho on Apr 6, 2016 14:53:02 GMT -5
I hope Matt has a sense of humor. I sure hope so! I truly think he is the best person for this job. I think he will make Al proud! |
|
|
|
Post by brotherm1 on Apr 6, 2016 16:09:47 GMT -5
Only makes sense to do it yourself. My father always said if you want something done right you need to do it yourself. I'm feeling very confident MNKD will find the necessary funds to get the job done right
|
|
|
|
Post by tayl5 on Apr 6, 2016 17:12:37 GMT -5
Excerpts:
“We think we know what went wrong in Sanofi's hands, and we think we can fix that,” said Matthew Pfeffer, MannKind's CEO.
In recent months MannKind hired Michael Castagna, a former VP and global commercial lead at Amgen, as chief commercial officer, tasking him with building a sales force targeting primary care physicians. It is in the midst of finalizing a contract with a new advertising agency. The company also changed its strategy, identifying new patient populations to target, evaluating new pricing tactics, and reopening discussions with payers.
The “Surprise, it's Insulin!” campaign, which was developed by Havas Health, primarily targeted patients in the early stages of a diagnosis with type 2 diabetes.
Still, Pfeffer viewed Sanofi's strategy as flawed and said it failed to include potential patient populations. “They ignored segments, like type 1,” he said. “We think that was a mistake.”
---
It appears, now that the License & Collaboration Agreement is terminated, CEO Pfeffer can be a lot more vocal about Sanofi's mishandling of Afrezza
The article is now corrected to say MannKind will be targeting endos, not PCPs. |
|
|
|
Post by mnholdem on Apr 6, 2016 17:43:02 GMT -5
Funny, but the author changed the first reference to PCP's but missed the second reference to targeting the PCPs, which I quoted above. It's farther down in the article and hasn't been edited. Regardless, I hope MannKind will target both Endos and PCPs, but the endocrinologist certainly makes sense if you plan to target Type I diabetics. Also, many PCP's will send a newly diagnosed diabetic to an Endo anyway.
I'm hearing many members on this and other forums, who have medical knowledge and/or experience with Afrezza, commenting that what is really needed is easy-to-understand instructions for how to dial in a patient to Afrezza. That makes a lot of sense to me because I've noticed that most advocates who have blogged their experiences with Afrezza had unique responses and varying dosage requirements. No two are really alike. Perhaps it can be argued that the comparison chart converting units of RAA insulin to units of Afrezza is a sufficient starting point because the patient has already determined how their body reacts to mealtime insulin, but the testimonials seem to indicate otherwise. I've read where Type 1's have even reduced their basal dosages after starting Afrezza.
If nothing else, my investment in MannKind has made me very aware of how complicated diabetes is. For that reason alone (if I may stray a bit) the company that successfully markets a low-cost Continuous Glucose Monitor (CGM) is likely to make a fortune.
|
|
|
|
Post by nylefty on Apr 6, 2016 17:51:49 GMT -5
FTA: “We're not going to hand over the product to another pharma company,” Pfeffer said. Lesson learned. Why does this remind me of the story about how Mr. Mann (RIP) got in the cochlear implant business? I think another meaning of FTA applies. Please share that story. I haven't heard it. |
|
/production/original_573352236.gif)
